This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
Clinical trial NCT02171260 · COMPLETED
Trial details
- NCT number
- NCT02171260
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-31
- Primary completion
- 2016-01-28
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.